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Progressive familial intrahepatic cholestasis type 2 (PFIC-2) is caused by mutations in
ABCB11, encoding the bile salt export pump (BSEP). In 2009, we described a child with
PFIC-2 who developed PFIC-like symptoms after orthotopic liver transplantation (OLT).
BSEP-reactive antibodies were demonstrated to account for disease recurrence. Here, we char-
acterize the nature of this antibody response in 7 more patients with antibody-induced BSEP
deficiency (AIBD). Gene sequencing and immunostaining of native liver biopsies indicated
absent or strongly reduced BSEP expression in all 7 PFIC-2 patients who suffered from pheno-
typic disease recurrence post-OLT. Immunofluorescence, western blotting analysis, and trans-
epithelial transport assays demonstrated immunoglobulin (Ig) G-class BSEP-reactive
antibodies in these patients. In all cases, the N-terminal half of BSEP was recognized, with
reaction against its first extracellular loop (ECL1) in six sera. In five, antibodies reactive against
the C-terminal half also were found. Only the sera recognizing ECL1 showed inhibition of
transepithelial taurocholate transport. In a vesicle-based functional assay, transport inhibition
by anti-BSEP antibodies binding from the cytosolic side was functionally proven as well.
Within 2 hours of perfusion with antibodies purified from 1 patient, rat liver showed canalicu-
lar IgG staining that was absent after perfusion with control IgG. Conclusions: PFIC-2 patients
carrying severe BSEP mutations are at risk of developing BSEP antibodies post-OLT. The anti-
body response is polyclonal, targeting both extra- and intracellular BSEP domains. ECL1, a
unique domain of BSEP, likely is a critical target involved in transport inhibition as demon-
strated in several patients with AIBD manifest as cholestasis. (HEPATOLOGY 2016;63:524-537)
P
rogressive familial intrahepatic cholestasis (PFIC)
is a group of inherited cholestatic diseases of
hepatocellular origin often starting in early
infancy.1,2 PFIC has an estimated incidence of 1-2 per
100,000 births3 and can be divided into three subtypes
with differences in clinical, biochemical, and histological
features (PFIC-1-3). PFIC-1, also termed Byler’s
disease, is characterized by normal gamma-glutamyl
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transpeptidase (GGT) levels and is associated with extra-
hepatic features such as pancreatitis, diarrhea, and hear-
ing impairment. It is caused by mutations in the
ATP8B1 gene4 encoding familial intrahepatic cholestasis
1 (FIC1), an aminophospholipid flippase. PFIC-2, like
PFIC-1, is associated with low GGT levels and caused
by mutations in the bile salt export pump (BSEP)
expressed by the ABCB11 (adenosine triphosphate bind-
ing cassette transporter, subfamily B, member 11) gene.
PFIC-2 is also referred to as BSEP deficiency.5 PFIC-3
is caused by mutations in the ABCB4 gene, which enco-
des the multidrug resistance protein 3, a phosphatidyl-
choline (PC) floppase.6,7 When PC is reduced in bile,
formation of mixed micelles is disturbed.8 The resulting
increase in free bile salts leads to injury of the biliary
tree, resulting in elevated GGT levels.7
BSEP is exclusively expressed in the microvillar
domains of the canalicular hepatocyte membrane9; it is
the principal transporter of bile salts from hepatocytes
into bile.9,10 Missense, nonsense, indel, or splice-site
mutations of ABCB11 may impair bile salt transport as
a result of reduced or absent protein expression, altered
splicing, disturbed protein processing and trafficking, or
reduced transmembrane transport.10 Milder forms of
BSEP deficiency are termed, depending on the clinical
setting, benign recurrent intrahepatic cholestasis type 2,
intrahepatic cholestasis of pregnancy, and drug-induced
liver injury.5
PFIC-2 manifests in infancy with jaundice, severe
intractable pruritus, diarrhea, complications of fat-
soluble vitamin deficiency, and growth failure.11 Serum
alanine aminotransferase activity and bile salt levels are
high; GGT levels are lower than expected for the degree
of conjugated hyperbilirubinemia. Histological features
of PFIC-2 at presentation are lobular and portal fibrosis
and inflammation, with intralobular cholestasis accom-
panying hepatocellular disarray, giant-cell change, and
necrosis, ascribed to retention of bile salts within
hepatocytes.3,12 In many patients, BSEP expression is
absent or reduced on immunohistochemical or
immunofluorescent study of liver tissue.13-15 Without
treatment, PFIC-2 progresses to end-stage liver disease,
sometimes with hepatobiliary malignancy,15,16 leading
to death in childhood.17 Only orthotopic liver trans-
plantation (OLT) yields good outcome in most PFIC-2
patients.5,11
In some patients with PFIC-2, a phenotype suggest-
ing recurrence of BSEP deficiency develops post-OLT.
In 2009, we described a girl with PFIC-2 caused by lack
of BSEP expression resulting from three homozygous
nucleotide substitutions in ABCB11. After OLT, her
serum contained high-affinity antibodies directed
against the first extracellular loop (ECL1) of BSEP, with
strong canalicular immunoglobulin (Ig) G deposits in
two consecutive liver allografts.18 We and others pro-
posed that BSEP-reactive antibodies cause cholestasis by
inhibiting BSEP transport activity.18,19 Since then, only
a few further cases of antibody-induced BSEP deficiency
(AIBD) have been reported.19-22 We here present a
detailed analysis of the BSEP-reactive antibody reper-
toire causing AIBD, and of these antibodies’ functional
effects, in sera from 7 more AIBD patients.
Patients and Methods
Additional method descriptions can be found in the
Supporting Information.
Patients. Charts of all patients in this study were
reviewed. Table 1 summarizes patient details, genetic
information, course of disease recurrence, and treatment
regimens. Serum samples for antibody detection were
stored at -208C. A liver sample from a noncholestatic
patient undergoing partial hepatectomy because of liver
metastasis of a colon carcinoma was used for detecting
antibodies in patients’ serum with canalicular reactivity.
Serum of a healthy 35-year-old man was used as a non-
OLT control throughout this study. All patients or their
parents gave written consent for investigation. This
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study was performed according to the guidelines of the
declaration of Helsinki.
ABCB11 Sequencing From Genomic DNA.
Genomic DNA was extracted using the QIAamp DNA
Blood Kit (Qiagen, Hilden, Germany). All 27 coding
exons of ABCB11, with exon-intron transitions, were
amplified and sequenced as previously described.23 Data
were compared with reference sequence NM_003742.2
(Gene ID: 8647); variations were verified by resequenc-
ing and designated according to the Human Genome
Variation Society guidelines.24
Immunofluorescence Staining of Liver Cryosec-
tions. As previously described,14,23 sera diluted up to
1:16,000 were tested for immunoreactivity using
methanol-fixed cryosections of noncholestatic human
liver. A murine monoclonal antibody against multidrug
resistance-associated protein 2 (M2I-4; Alexis,
Gr€unberg, Germany) served as a canalicular marker
(used at 1:25). Goat anti-human IgG/cyanine 3 (Cy3;
Jackson ImmunoResearch Laboratories, West Grove,
PA) and goat anti-mouse IgG/Alexa Fluor 488 (Invitro-
gen, Karlsruhe, Germany) were used as secondary anti-
bodies (each at 1:500). For detection of canalicular IgG
deposits, fixed cryosections of patient transplant liver
biopsies and perfused rat liver were immunostained as
described above. BSEP expression in native liver of
patient 1 was analyzed using the K24 antiserum raised
against the C-terminus of human BSEP.25 Specimens
were analyzed with a LSM 510 Meta confocal laser scan-
ning microscope (Zeiss, Jena, Germany).
Analysis of Patient Sera for anti-BSEP Reactivity
in Transiently Transfected HEK293 Cells. HEK293
(human embryonic kidney) cells were transiently
transfected with wild type (WT) BSEP-EYFP
(enhanced yellow fluorescent protein), BSEP-1-659-
EYFP, or BSEP-659-1321-EYFP18 using X-treme
Gene HP (Roche Applied Science, Mannheim, Ger-
many). After 48 hours, cells were fixed with ice-cold
methanol for 30 seconds and stained with human sera
(1:50) for 1 hour using goat anti-human IgG/Cy3 as
the secondary antibody (1:500). The monoclonal anti-
BSEP antibody, F-6 (Santa Cruz Biotechnology, Hei-
delberg, Germany), served as a positive staining con-
trol (1:100), with goat anti-mouse IgG/Cy3 as
secondary antibody (1:500). Cell nuclei were stained
with Hoechst 34580 or 40,6-diamidino-2-phenylindole
(Invitrogen). Cells were visualized by confocal laser-
scanning microscopy.
Cloning, Expression, and Purification of the First
Extracellular Loop of Human BSEP. The first
extracellular loop of human BSEP, with an N-terminal
hexahistidine tag for purification, was expressed as a
C-terminal EYFP fusion protein (ECL1-EYFP) in
Escherichia coli (see Supporting Information for details
of cloning strategy, expression, and purification).
Analysis of Patient Sera for Anti-BSEP Reactivity
by Western Blotting. Ten micrograms of Sf 9 mem-
brane vesicles (either empty control vesicles or vesicles
containing human BSEP; Solvo Biotechnology, Buda-
pest, Hungary) or 0.5 lg of purified ECL1-EYFP were
separated by sodium dodecyl sulfate (SDS) polyacryl-
amide gel electrophoresis and transferred onto nitrocel-
lulose membranes. For detection of BSEP-reactive IgG,
membranes were first incubated for 1 hour with patient
or control serum (1:100) followed by goat anti-human
IgG/horseradish peroxidase (1:10,000) as the secondary
antibody. The anti-BSEP antibody F-6 was used at
1:1,000 as a positive control.
Transepithelial Transport Assays. Generation of
LLC-PK1 cells stably expressing BSEP and/or NTCP
(the Na1/taurocholate cotransporting polypeptide, here
facilitating cellular uptake of taurocholate [TC]) is
described in the Supporting Information. For transepi-
thelial transport studies, cells were seeded at high density
onto ThinCertTM cell-culture inserts (0.4-lm pore size;
Greiner Bio One, Frickenhausen, Germany) and cul-
tured for 2 days. Cell monolayers were routinely used at
a net transepithelial electric resistance of at least 500
Xcm2. To compensate for the lack of CO2-enriched
atmosphere during the transport inhibition studies,
both apical and basal medium were exchanged for 1 and
2 mL, respectively, of 25 mM of HEPES buffered
medium (pH, 7.5). Then, 100 lL of apical medium
were replaced by either patient or control serum (thus
diluted 1:10) for overnight incubation of the apical face
of the cell monolayer. Alternatively, 4 lg of F-6 anti-
body, which does not recognize ECL1, was used as a
negative control. A mixture of 1 mM of unlabeled
sodium TC (Sigma-Aldrich, St. Louis, MO) and 200
lM of [3H]-TC (PerkinElmer, Waltham, MA) at a ratio
of 1:100 was added to the basal medium to a final con-
centration of 5 lM, and cells were incubated for 1 hour
at 378C. Then, cell-culture inserts were removed, apical
and basal media were collected, and inserts were gently
washed three times on their apical and basal sides with 1
and 2 mL of ice-cold phosphate-buffered saline (PBS),
respectively. Finally, the cell monolayer was lysed in 500
lL of 0.5 M of NaOH with 0.1% (w/v) SDS. Then,
250 lL of each cell lysate (or 500 lL of medium) was
mixed with 4 mL of liquid scintillation fluid (Ultima
Gold; BD Biosciences, Heidelberg, Germany) for 20
seconds before measurement in a scintillation counter
(Packard Instruments, Frankfurt, Germany).
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BSEP Inhibition by Patient IgG in Vesicular
Transport Assays. Transport activity of human
recombinant BSEP was measured in Sf9 membrane
vesicles. For incorporation of antibodies into the vesic-
ular lumen, an adapted freeze-thaw technique26 was
applied. Briefly, purified patient IgG was added to
thawed vesicles by gentle pipetting, and the prepara-
tion was repeatedly snap-frozen and allowed to thaw
slowly on ice. In order to study BSEP transport inhi-
bition from the “intracellular” (extravesicular) side
alone, IgG was added as described above and samples
were kept on ice as long as those subjected to freeze-
thaw cycles.
Rat Liver Perfusion. Animals received care
according to the Guide for the Care and Use of Labo-
ratory Animals (NIH publication 86-23, revised 1985;
and Australian Psychological Society guidelines). The
study protocol was approved by the local authorities.
Livers of male Wistar rats (body weight approximately
150 g) were perfused in a nonrecirculating system as
previously described.27 Liver weight was estimated to
be 3.5% of total body weight; flow rate was adjusted
to 3.7 mL/(g liver*min). TC was perfused throughout
the experiment at a concentration of 100 lM in order
to saturate bile salt transport. After 30 minutes,
Krebs-Henseleit buffer containing 6.57 mg/L of either
control or patient IgG was perfused. After 120
minutes, the right ventral liver lobe was harvested and
snap-frozen in liquid nitrogen for cryosectioning and
immunostaining.
Statistical Analysis. Column diagrams were pre-
pared using Prism (version 5.0a, GraphPad) and signifi-
cances shown in Fig. 6 were calculated using the Student
t test function (unpaired; two-sided P values).
Fig. 1. AIBD sera specifically recognize human BSEP. (A) Post-OLT sera from AIBD patient 1 and a non-AIBD, PFIC-2 control yield canalicular
staining patterns in cryosections of healthy human liver whereas na€ıve, non-OLT control serum does not. MRP2 was immunostained as a canalic-
ular marker. The non-AIBD control sera only stain up to dilutions of 1:100, whereas all AIBD sera stain at maximal dilutions ranging from
1:1,000 up to 1:16,000. (B) All AIBD sera recognize human full-length BSEP-EYFP expressed in HEK293 cells (patient serum 1 shown). In con-
trast, non-AIBD sera do not recognize BSEP (non-AIBD PFIC-2 control shown). Bars 5 10 lm. (C) Likewise, only the seven AIBD sera detect
recombinant human BSEP (expressed in Sf9 cells) on nitrocellulose membranes (Ctrl, empty control vesicles; BSEP, vesicles containing human
BSEP). The non-AIBD, PFIC-2 control likely had some BSEP expression before OLT and did not develop a subsequent humoral response whereas
the non-AIBD, non-PFIC-2 control had normal BSEP expression and suffered from an unrelated liver condition. Notably, the asymptomatic brother
of patient 3 who had the same homozygous PFIC-2 mutation had serum reactivity against BSEP. F-6, monoclonal BSEP antibody. Apparent
molecular weight of BSEP is 150 kDa. The full data set of all patients is shown in Supporting Figs. 1 and 2.
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Results
AIBD Sera Specifically Recognize Human BSEP
With a High Titer. We examined sera from 9
patients (1) diagnosed with PFIC-2 or low-GGT intra-
hepatic cholestasis, (2) that had undergone OLT, and
(3) who showed symptoms compatible with disease
recurrence. Their clinical and laboratory data are sum-
marized in Table 1. Serum samples taken at the time of
symptom recurrence were tested for canalicular immu-
noreactivity with histopathological sections from normal
human liver (Fig. 1A; see Supporting Fig. 1 for the com-
plete data set). All nine post-OLT sera, but not na€ıve
control serum, yielded a canalicular staining pattern,
albeit at very different titers (Table 1). Anticanalicular
antibodies were detectable at serum dilutions from
1:1,000 up to 1:16,000 for 7 patients (numbered 1 to
7), whereas serum titers of canalicular reactivity were
very low with a maximum of 1:100 for 2 patients (num-
bered 8 and 9). To test for specific reactivity against
BSEP, serum samples were then analyzed by immunoflu-
orescence using HEK293 cells transiently transfected
with human BSEP-EYFP. All seven high-titer sera recog-
nized recombinant BSEP in transfected cells (Fig. 1B
and Supporting Fig. 2), that is, they contained anti-
BSEP antibodies. This was further confirmed by immu-
noblotting analysis, in which only the sera 1-7 specifi-
cally detected recombinantly expressed human BSEP
(Fig. 1C). Therefore, AIBD was diagnosed in 7 of 9
patients collected by the three criteria stated above
(patients 1 to 7).
In contrast, sera from patients 8 and 9 did not recog-
nize recombinant BSEP (immunofluorescence and
immunoblotting) and were classified as non-AIBD
cases. Patient 8 was a case of PFIC-2 caused by two mis-
sense mutations (Table 1) treated by OLT. He suffered
from a cholestatic episode with elevated GGT-levels
obviously not caused by a humoral anti-BSEP response.
Consequently, his serum was used as a PFIC-2,
non-AIBD control, which is representative of the major-
ity of tranplanted, asymptomatic PFIC-2 patients.18
Patient 9 was initially diagnosed as having low-GGT
PFIC and was soon after transplanted because of his
severe condition. A biopsy of his native liver showed
normal canalicular expression of FIC1, BSEP, and mul-
tidrug resistance (MDR) 3 (not shown). PFIC-1 and
PFIC-2 were eventually excluded by sequencing of the
ATP8B1 and ABCB11 genes. Hence, his serum was used
as a non-PFIC-2, non-AIBD control. Notably, patient 3
had a brother who suffered from the same PFIC-2
mutations as his sister and therefore had to be trans-
planted at the age of 1.5 years. Although he remained
asymptomatic, anti-BSEP antibodies were detected in
his serum at a titer of 1:1,600 (western blotting in Fig.
1C) 3 years post-OLT.
AIBD Patients Lack Normal BSEP Expression in
Native Liver. Absence of BSEP expression in the
native liver has been postulated to be a prerequisite for
the development of anti-BSEP antibodies.18-20,22 In line
with this, BSEP was not detectable by immunohisto-
chemistry in native livers of patients 3-7 (Table 1).
Patient 2 was homozygous for the nonsense mutation
p.Q971X, thus absence of BSEP in his native liver can
be assumed. Only in patient 1 was a residual wildtype
BSEP expression clearly demonstrated (Fig. 2), as shown
by the use of the K24 antibody, which recognized the
carboxy (C)-terminus of BSEP. In this patient, one
ABCB11 allele was affected by a c.15013A>C splice-
site mutation, whereas a five-nucleotide insertion
Fig. 2. Canalicular wildtype BSEP expression is clearly detectable in the native liver of AIBD patient 1. The K24 antiserum used for BSEP
detection was raised against the carboxy-terminus of BSEP and thus only recognizes the full-length, wildtype gene product from the splice-site-
mutated ABCB11 allele. MRP2 was immunostained as a canalicular marker. Bar 5 10 lm.
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(c.2783_2787dup5) on the other resulted in a frame-
shift causing the hypothetical protein truncation
p.K930Efs79X (Table 1). The remainder of BSEP
detected by K24 in his native liver was therefore
expressed from the allele carrying the intronic splice-site
mutation, encoding the WT protein with its intact C-
terminus.
Changes in Immunosuppression, Viral Infections, and
Episodes of Acute Rejection May Trigger AIBD. We
reviewed the clinical history of all seven AIBD cases
in order to identify triggering factors for the devel-
opment of BSEP-reactive antibodies post-OLT (sum-
marized in Table 1). Cholestasis began to recur
from 3 to 108 months post-transplantation. In four
of the seven cases, this coincided with a change or
decrease of immunosuppressants. In two of these,
subsequent transplant rejection was reported. Also,
two cases suffered from viral infections (Epstein-Barr
virus, hepatitis B virus) at the time of phenotypic
disease recurrence. In contrast, neither ischemia
reperfusion injury nor biliary injury was documented
for any of the AIBD patients or non-AIBD controls,
while bouts of acute rejection preceding any poten-
tial trigger events were only reported for 1 AIBD
patient (see Supporting Table 1).
The First Extracellular Loop of BSEP Is a Common
Target of the Antibody Response in AIBD. Because
the first AIBD case study18 identified a sequence within
ECL1 as the target of the patient’s BSEP-reactive anti-
body response, we screened all AIBD sera for specific
reactivity toward ECL1. Topological considerations pre-
dict that ECL1 is the largest extracellular domain of
BSEP, with 61 amino acid residues18,28; by comparison,
ECL2 to ECL6 comprise 4, 20, 20, 4, and 4 residues,
respectively. This domain is unique to BSEP and has
only minimal homologies to the corresponding loop of
MDR1 and MDR3 (MDR1: 18%; MDR3: 21% iden-
tity; Fig. 3A). ECL1 was recombinantly expressed in E.
coli as a fusion protein with a hexahistidine and an
EYFP tag (Supporting Fig. 3). Using the purified
recombinant epitope, we found ECL1-reactive IgG in
nearly all AIBD sera, with the exception of patient 6. In
Fig. 3. The first extracellular loop of BSEP is a recurrent, likely critical target of the AIBD response. (A) A homology model of BSEP based on
the crystal structure of SAV18662 suggests that ECL1 (61 amino acid residues [aa]; aa that could be modeled are shown in red; the red circle
is intended to give an approximate impression of its actual size) is both a large and potentially accessible epitope. It is unique to BSEP and not
found in the closely related MDR3 (ABCB4) or MDR1 (ABCB1). Only a few aa at the edges of ECL1 are conserved between ECL1 and the corre-
sponding loops of MDR1/MDR3 (yellow), whereas a comparison of the remainder of BSEP with its homologs shows higher conservation (green).
(B) The ECL1 of BSEP was expressed as a C-terminal EYFP fusion protein in E. coli and purified by its N-terminal hexahistidine tag. The epitope
is frequently recognized by the immune response of AIBD patients; six of the seven BSEP-reactive antisera detected it when blotted onto nitrocel-
lulose membranes. Interestingly, ECL1 was not detected by the BSEP-reactive serum response from the transplanted, asymptomatic brother of
patient 3.
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contrast, both non-AIBD control sera failed to recognize
ECL1 (Fig. 3B). Strikingly, the transplanted (PFIC-2),
asymptomatic brother of patient 3 had no ECL1 reactiv-
ity in his serum sample whereas his serum antibodies
recognized full-length BSEP. The lack of reactivity in all
controls also demonstrates that the human IgG pool is
devoid of unspecific reactivity against the EYFP domain
of the fusion protein.
AIBD Sera Inhibit Human BSEP From the
Extracellular Side. The inhibitory capacity of anti-
BSEP antibodies was analyzed in a cell- and a vesicle-
based transport assay. We generated a double-transduced
LLC-PK1 cell line expressing human NTCP at the baso-
lateral membrane and BSEP at the apical membrane
(Fig. 4A), resulting in the vectorial transport of [3H]-
TC from the basal into the apical compartment (Fig.
4A,B). Untransduced LLC-PK1 cells, as with cells
expressing exclusively NTCP or BSEP, showed no signif-
icant transepithelial [3H]-TC transport (Supporting Fig.
4). In double-transduced cells, inhibition of both BSEP
and NTCP activity by 50 lM of cyclosporin A (CsA)
resulted in a reduced intracellular uptake of [3H]-TC,
whereas inhibition of BSEP activity alone by 50 lM of
rifampicin led to an increase in intracellular [3H]-TC
content (Fig. 4B). When the apical face of the double-
transduced LLC-PK1 cells was preincubated overnight
Fig. 4. AIBD sera inhibit BSEP-mediated transport in a polarized cell culture model. (A) Concept of the transepithelial transport assay. Inset,
X/Z-section of the NTCP-mCherry (red)/BSEP-EYFP (green) double-transduced LLC-PK1 cell line used in this assay. The intracellular volume of the
monolayer is estimated to be around five orders of magnitude less than those of the apical and basolateral compartments. Accordingly, the intra-
cellular equilibrium generated by influx from the source (basal compartment) and efflux to the sink (apical compartment) is much more sensitive
to extracellular inhibition of TC efflux by BSEP whereas both the source and the sink compartment do not show significant changes upon apical
serum incubation. (B) Inhibition of BSEP and NTCP/BSEP activity by rifampicin and CsA, respectively, indicates functionality of both transporter
proteins. Cell monolayers were preincubated for 1 hour with these agents, applied apically. (C) Inhibition of BSEP-mediated transepithelial trans-
port of TC in LLC-PK1 cells by overnight apical incubation with AIBD and non-ABID control sera. Only incubation of cell monolayers with AIBD
sera led to an increase in intracellular TC (imported by NTCP from the basal compartment). Notably, serum from patient 6, showing no BSEP
inhibition, was the only AIBD patient serum incapable of detecting ECL1 (see Fig. 3B). Columns and error bars represent the mean and standard
error of two independent measurements. un, untreated.
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with AIBD sera, intracellular amounts of [3H]-TC
increased; this was ascribed to antibody-mediated inhi-
bition of BSEP activity (also see Supporting Fig. 4 for
an illustrative comparison of the different transgenic
LLC-PK1 cell lines). This BSEP inhibition was observed
in the presence of all AIBD sera except patient 6 (Fig.
4C), who lacked serum reactivity against ECL1 (see Fig.
3B). In contrast, BSEP activity was not inhibited by the
non-AIBD controls, na€ıve control serum or the mono-
clonal anti-BSEP antibody, F-6, which was raised against
the N-terminal 180 amino acid residues but did not rec-
ognize ECL1.
AIBD Antibodies Detect Multiple Epitopes of
BSEP and Inhibit Its Function From Intra- and
Extracellular Sides. Whether AIBD antibodies react
with one or several distinct domains of BSEP is
unknown. To investigate this, we stained HEK293 cells
transiently expressing either the N- or C-terminal half
of BSEP18 with patients’ sera. As shown in Fig. 5A for
patient 1, all AIBD sera recognized the N-terminus of
BSEP, which contains ECL1 (for the complete set, see
Supporting Figs. 5 and 6). The majority of sera also rec-
ognized the C-terminal half of BSEP (Fig. 5B), with
two sera (2 and 5) showing little or no reactivity. Non-
AIBD sera and the na€ıve control failed to recognize
either the N- or C-terminal BSEP half.
Where sample material sufficed, total IgG from
AIBD patient serum was purified for in vitro inhibition
studies using human recombinant BSEP expressed in
insect cell membrane vesicles (Fig. 6). To differentiate
between intra- and extracellular inhibition, we measured
transport activity in vesicles prepared with or without
freeze/thaw cycles (Fig. 6A). By applying repeated
freeze/thaw cycles, the antibodies were incorporated into
the vesicular lumina, thus exposing both the intra- and
extracellular sides of BSEP to patients’ IgGs. In vesicles,
which were not prepared by freeze/thaw cycles, BSEP
was only accessible from the extravesicular side. The
variable IgG concentrations reflect variable amounts of
available serum, which, in some cases, was limiting (Fig.
6B; see IgG concentrations). Using this assay, we could
confirm that all tested AIBD sera demonstrated IgG-
mediated BSEP inhibition (Fig. 6B, white bars), ranging
from approximately 6.9% to 21.6% per mg/mL total
patient IgG. In contrast, the low-concentration IgG
from patient 7 only showed a slight inhibition. IgG
amounts from patient 6 allowed only for one assay
mode, so the freeze/thaw variant was chosen for maxi-
mal accessibility of BSEP. In the remaining three AIBD
IgG pools (patients 2-4), BSEP inhibition was signifi-
cantly more effective when the transporter was accessible
from both sides (white bars) than when it was accessible
from the “intracellular” (extravesicular) side only (gray
bars). Taken together, our findings demonstrate that
BSEP recognition and inhibition are indeed aspects of a
polyclonal antibody response directed against both
intra- and extracellular portions of BSEP.
BSEP-Reactive IgG Rapidly Decorates Canalicu-
lar BSEP in Perfused Rat Liver. So far, strong IgG
deposits in the canalicular space of liver from an AIBD
Fig. 5. AIBD sera stain HEK293 cells transiently expressing the N- or C-terminal halves of BSEP. (A and B) As exemplified by patient 1, all
AIBD sera except those from patients 2 and 5 recognize both halves; the exceptions show little or no reactivity against the C-terminal half. In
contrast, the non-AIBD controls and na€ıve control serum fail to detect either half of BSEP. Likely owing to its lack of the native N-terminal signal
anchor sequence, the C-terminal half is largely retained intracellularly. Bars 5 10 lm.
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patient have only once been described.18 In our cohort,
biopsy materials from allograft livers were available for
all AIBD cases except patient 6. We could detect a clear
canalicular IgG staining pattern using an anti-human
IgG antibody in all available AIBD liver samples (Sup-
porting Fig. 7). In contrast, no IgG was detected in the
canaliculi of transplant biopsies from the non-AIBD
controls. To find out whether and how fast BSEP-
reactive IgG reaches the canalicular space in intact
organs, rat livers were perfused in situ for 2 hours (Fig.
7). Rat Bsep is highly homologous to human BSEP and
it has been shown previously that human AIBD sera
recognize rat Bsep.18,19 Using purified total IgG from
patient 4 (16 mg), we observed a distinct, patch-like
canalicular staining (Fig. 7B) that was absent when using
an equal amount of na€ıve control IgG (Fig. 7A). This
indicates that anti-BSEP IgG antibodies rapidly reach
the canalicular space. Of note, we did not observe a
Fig. 6. BSEP-mediated TC transport in a vesicular assay is inhibited from the extra- as well as the intraluminal side. (A) Concept of the
different vesicle incubation methods used in this assay. The red and dark gray antibodies recognize extra- and intracellular epitopes of
BSEP, respectively. In essence, BSEP may be inhibited either (1) solely from its intracellular side or (2) from both its intracellular and its
extracellular side. [3H]-TC uptake by rapid filtration can be measured only using inside-out vesicles such as those shown here, which
expose nucleotide-binding domains to ATP-containing buffer. (B) Purified patient IgGs were incorporated into the lumina of Sf9 membrane
vesicles containing human BSEP by multiple freeze/thaw steps (white columns). Thus, BSEP-reactive antibodies can bind their targets on
the outside of assayable (i.e., inside-out) vesicles as well as on the intraluminal (“extracellular”) side (see (A, ii). Alternatively, BSEP
vesicles were incubated on ice for the same duration with same amounts of patient IgG (gray columns). Here, only extravesicular
(“intracellular”) parts of BSEP are accessible to patient antibodies (see A, i). Data in (B) represent mean and standard error of three inde-
pendent measurements and were analyzed using the Student t test (unpaired; two-sided P values). *P < 0.05; **P < 0.005; ***P <
0.0005; n.s., not significant.
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change in bile salt-dependent bile flow (not shown),
which likely is owing to incomplete antibody saturation
of canalicular BSEP during the short time of perfusion.
Discussion
The development of anti-BSEP antibodies in PFIC-2
patients post-OLT was first described in 2009 by us and
others.18,19 This study demonstrates, for the first time,
the polyclonal nature of the BSEP-reactive antibody rep-
ertoire, which targets epitopes on both N- and C-
terminal halves of BSEP. Furthermore, anti-BSEP anti-
bodies bind to both intra- and extracellular domains,
inhibiting bile salt transport (Fig. 6). However, on intact
hepatocytes only extracellular epitopes are accessible to
antibodies from the canalicular lumen. Accordingly,
only antibodies directed against extracellular structures
can inhibit BSEP function in vivo and are thus of patho-
physiological importance. Notably, Jara et al. demon-
strated in vitro inhibition of BSEP-mediated transport
after incubation of insect cell membrane vesicles with
AIBD patient sera.19 In the rapid filtration assay that
they used, the buffer solution bathing the vesicles con-
tained adenosine triphosphate (ATP), magnesium, and
the inhibitory antibodies. Only when vesicular mem-
branes are oriented inside-out, exposing the intracellular
nucleotide-binding domains of BSEP to ATP, BSEP can
transport the radiolabeled substrate into the vesicular
lumen (compare Fig. 6A). Hence, the inhibition that
Jara et al. demonstrated for three BSEP-reactive sera
could only result from binding of IgG reactive toward
intracellular BSEP domains. Upon inclusion of BSEP-
reactive IgG within the vesicular lumen, we found a sig-
nificantly higher decrease in transport, indicating that
BSEP was inhibited from both the intra- and extracellu-
lar sides (Fig. 6B).
Unlike isolated vesicles, the closed polarized LLC-
PK1 cell monolayer only permits binding of antibodies
to extracellular epitopes on intact cells. Preincubation of
the apical cell surface with AIBD sera led to an increase
in intracellular TC concentrations in this transport assay
(Fig. 4C). That this effect was moderate may be owing
to the small amounts of patient IgGs used, resulting in
only partial or incomplete BSEP inhibition. Addition-
ally, the extracellular matrix of the dense LLC-PK1 cell
monolayer may also reduce antibody access to BSEP.
However, because the intracellular volume of the mono-
layer is much smaller than that of both medium-
containing compartments, even small changes in TC
influx or efflux are expected to result in a measurable
change in cellular [3H]-TC content.
A BSEP homology model based on the SAV18662
ABC transporter structure29 indicates that ECL1 is the
largest domain of BSEP accessible to antibodies from
Fig. 7. BSEP-reactive IgG rapidly decorates canalicular BSEP in perfused rat liver. Rat livers were perfused in situ for 2 hours with equal
amounts of total IgG purified from either (A) a na€ıve control or (B) AIBD patient 4 (from whom sufficient IgG could be obtained by purification
from serum retained on immunoadsorption columns). Only perfusion with BSEP-reactive IgG resulted in a canalicular pattern of colocalization of
variable extent (yellow in the merge panels) of human antibodies (red) with the canalicular marker Mrp2 (green). Na€ıve IgG stained only the sinu-
soids. Colocalized pixels are shown in white in the lower right panels. Bars 5 50 lm.
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the extracellular space (Fig. 3A). This domain is exclu-
sively found in BSEP (ABCB11, also called sister of
P-glycoprotein), but not in any other of its close rela-
tives such as MDR1 (ABCB1, P-glycoprotein) and
MDR3 (ABCB4; Fig. 3A, right panels) and likely has
some unique functional role yet to be uncovered. We
previously identified this domain as the target of an
AIBD patient’s anti-BSEP response.18 Indeed, ECL1
was found to be a recurrent and likely critical target of
the AIBD antibody response (Fig. 3). This is also sup-
ported by our finding that the serum of patient 6,
devoid of reactivity against ECL1, failed to inhibit
BSEP from the extracellular side in the transepithelial
transport system (Fig. 4). Unfortunately, no biopsy
material was available to check this patient’s allograft for
canalicular IgG deposits. Ultimately, some uncertainty
remains whether this patient suffered from “true” AIBD
because he eventually died from severe bleeding compli-
cations caused by a necrotizing pancreatitis 1.5 years
after the detection of anti-BSEP antibodies. The notion
of ECL1 as a critical extracellular epitope is further sup-
ported by the finding that serum from the asymptom-
atic, transplanted brother of patient 3 lacked reactivity
against this domain while recognizing full-length BSEP
(Fig. 3B). Clearly, he was not affected by AIBD. Taken
together, which epitopes are recognized determines dif-
ferences in severity and outcome of AIBD in individual
patients.
After activation and proliferation of BSEP-reactive B
cells, anti-BSEP antibodies reach the canalicular space of
the allograft liver where they exert their inhibitory func-
tion. We could previously show that only BSEP-reactive
IgG decorates the canalicular membrane.18 In the study
by Jara et al., livers of Wistar rats injected with BSEP-
reactive patient serum at 48 and 24 hours before sacri-
fice showed canalicular staining specific for human IgG
that was absent when using normal serum.19 Strikingly,
this canalicular antibody deposition is already detected
after 2 hours of perfusion in rat liver (Fig. 7B). More-
over, BSEP-reactive IgG deposits may be considered a
general diagnostic feature of AIBD, given that we could
find these exclusively in allograft liver biopsy specimens
from AIBD patients (Supporting Fig. 7).
Four findings overall strongly suggest a pathophysio-
logical role of BSEP-reactive antibodies in AIBD: (1)
recognition of extracellular BSEP epitopes; (2) capacity
of antibodies binding to extracellular BSEP epitopes to
inhibit BSEP function; (3) targeting of anti-BSEP anti-
bodies to the canalicular membrane in vivo; and (4) can-
alicular antibody deposits in AIBD patients, but not in
patients with intrahepatic cholestasis after OLT who lack
anti-BSEP antibodies. The relevance of these antibodies
as mediators of AIBD is also underlined by the clinical
observation that AIBD symptoms are temporarily allevi-
ated by immunoadsorption,18 which removes antibodies
from the circulation, and by treatment with rituximab,22
a chimeric monoclonal therapeutic anti-CD20 antibody
that induces B-cell depletion and is used for the treat-
ment of autoimmune diseases. Rituximab treatment
induced remission of cholestasis in patients 1, 4, and 5
in this study. Patient 6 passed away from unrelated com-
plications and thus could not benefit from similar treat-
ment. Successful treatment by rituximab also suggests
that affected bile canaliculi must eventually undergo
antibody clearance.
It has been speculated that complete absence of BSEP
expression is a prerequisite for development of BSEP-
reactive antibodies post-OLT.18,20,30 In line with this, all
our patients who developed post-transplant anti-BSEP
antibodies carried mutations with predicted severe
effects on both ABCB11 alleles. Specifically, no missense
mutations were found among our AIBD patients, but
instead only nonsense, frameshift, or splice-site muta-
tions (Table 1). Notably, one AIBD case (patient 1) had
demonstrable, albeit strongly reduced, canalicular WT
BSEP expression in his native liver (Fig. 1), yet post-
OLT developed anti-BSEP antibodies. In general, cen-
tral tolerance against tissue-specific antigens (TSAs)
such as BSEP is obtained by clonal deletion (by apopto-
sis) of autoreactive T cells in the thymus, whereas auto-
reactive B cells in bone marrow are controlled both by
clonal deletion and receptor editing.31-33 Whereas the
B-cell repertoire is known to contain low-affinity, auto-
reactive B-cell receptors, which normally broaden the
initial humoral immune response, any BSEP-reactive B
cell requires a “fitting” T-helper cell for coactivation,
which recognizes the same antigen by its T-cell receptor
(TCR). In thymus, medullary thymic epithelial cells
(mTECs) stochastically express an abundant variety of
peptides derived from TSAs. Any TCR binding to these
peptide-MHC complexes is removed from the TCR
pool along with its T cell by apoptosis. Although small
amounts of mature, fully spliced messenger RNA
(mRNA) in the presence of the splice-site mutation,
c.15013A>C, could be detected in the native liver of
patient 1 (Dr€oge et al., in preparation), it is well con-
ceivable that mRNA processing within mTECs was inef-
fective for sufficient peptide production, resulting in
impaired clonal deletion of BSEP-reactive T cells.
Peripheral tolerance against transplanted BSEP on the
other hand would require constant antigen expo-
sure.34,35 In this context, BSEP may be regarded as a
conditionally sequestered antigen. Residing in the cana-
licular membrane, it remains inaccessible to cellular
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components of the immune system and is only released
into the circulation upon acute hepatocellular damage,
which then may trigger antibody production. Taken
together, AIBD should also be considered in trans-
planted PFIC-2 patients with a residual BSEP expres-
sion before OLT upon symptom recurrence.
Some important pathomechanistic questions of
AIBD remain to be addressed. It is still unclear how the
BSEP-reactive antibodies reach the canalicular space,30
as is by what mechanism(s) the polyclonal antibody rep-
ertoire inhibits BSEP function in vivo. Binding to the
extracellular side of BSEP may occlude the translocation
pore18 or impose other conformational restrictions that
prevent transporter function. Additionally, antibody-
mediated cross-linking of BSEP molecules in the cana-
licular membrane may contribute to functional inhibi-
tion by sequestering BSEP into larger aggregates that, in
turn, may disrupt the unique structure and asymmetry
of this membrane environment. Answers to these ques-
tions hold the key to a better understanding of AIBD
pathogenesis and to find improved means of treatment
or altogether prevent this severe type of acquired
cholestasis.
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